AR052052A1 - Terapia de combinacion - Google Patents

Terapia de combinacion

Info

Publication number
AR052052A1
AR052052A1 ARP050105303A ARP050105303A AR052052A1 AR 052052 A1 AR052052 A1 AR 052052A1 AR P050105303 A ARP050105303 A AR P050105303A AR P050105303 A ARP050105303 A AR P050105303A AR 052052 A1 AR052052 A1 AR 052052A1
Authority
AR
Argentina
Prior art keywords
combination therapy
hydrochlorothiazide
telmisartan
angiotensin
treatment
Prior art date
Application number
ARP050105303A
Other languages
English (en)
Spanish (es)
Inventor
Helmut E Schumacher
Axel Riedel
Peter Bohm
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35589356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR052052(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR052052A1 publication Critical patent/AR052052A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)
ARP050105303A 2004-12-17 2005-12-16 Terapia de combinacion AR052052A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63706204P 2004-12-17 2004-12-17

Publications (1)

Publication Number Publication Date
AR052052A1 true AR052052A1 (es) 2007-02-28

Family

ID=35589356

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105303A AR052052A1 (es) 2004-12-17 2005-12-16 Terapia de combinacion

Country Status (15)

Country Link
EP (1) EP1827424A1 (enExample)
JP (1) JP2008524136A (enExample)
KR (1) KR20070097511A (enExample)
CN (1) CN101080225A (enExample)
AR (1) AR052052A1 (enExample)
AU (1) AU2005315855A1 (enExample)
BR (1) BRPI0519656A2 (enExample)
CA (1) CA2589493A1 (enExample)
EA (1) EA200701159A1 (enExample)
IL (1) IL183944A0 (enExample)
NO (1) NO20072325L (enExample)
PE (1) PE20060768A1 (enExample)
TW (1) TW200637546A (enExample)
UY (1) UY29274A1 (enExample)
WO (1) WO2006063737A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US8637078B2 (en) 2005-11-24 2014-01-28 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and diuretic
EP1970053A1 (en) * 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical composition
RU2465916C2 (ru) * 2007-10-19 2012-11-10 Оцука Фармасьютикал Ко., Лтд. Твердый фармацевтический препарат матричного типа
WO2009058950A2 (en) 2007-10-30 2009-05-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
EP2252273B1 (en) 2008-03-19 2016-12-28 ratiopharm GmbH Solid pharmaceutical composition comprising a non-peptide angiotensin ii receptor antagonist and a diuretic
WO2010013835A2 (en) * 2008-07-31 2010-02-04 Takeda Pharmaceutical Company Limited Solid pharmaceutical composition
GB0822170D0 (en) * 2008-12-04 2009-01-14 Arrow Int Ltd Telmisartan with diuretic formulations
WO2010146187A2 (en) 2009-06-19 2010-12-23 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of telmisartan
WO2011002423A2 (en) * 2009-07-02 2011-01-06 Mahmut Bilgic Solubility enhancing pharmaceutical composition
WO2011002425A2 (en) * 2009-07-02 2011-01-06 Bilgig Mahmut Pharmaceutical composition increasing solubility and stability
TR200906506A2 (tr) 2009-08-24 2011-03-21 Bi̇lgi̇ç Mahmut Telmisartan içeren katı dozaj formları.
WO2011161123A2 (en) 2010-06-21 2011-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Multilayer pharmaceutical tablet comprising telmisartan and a diuretic
EP2952196A4 (en) * 2013-01-31 2016-08-03 Sawai Seiyaku Kk MULTILAYER TABLET WITH TELMISARTAN AND HYDROCHLOROTHIAZIDE
JP6422868B2 (ja) 2013-07-23 2018-11-14 第一三共株式会社 高血圧症の予防又は治療のための医薬
CN106562973A (zh) * 2016-11-06 2017-04-19 成都先先先生物科技有限公司 一种抗高血压药物复方制剂
CN107501192A (zh) * 2017-08-15 2017-12-22 中国科学院上海药物研究所 替米沙坦与氢氯噻嗪的共晶
CN108653227A (zh) * 2018-08-09 2018-10-16 湖北舒邦药业有限公司 一种替米沙坦氢氯噻嗪片及其制备方法
EP4029867A1 (en) * 2021-01-13 2022-07-20 Alpha Cognition Inc. Solid forms of galantamine benzoate gluconate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4229085C2 (de) * 1992-09-01 1996-07-11 Boehringer Mannheim Gmbh Längliche, teilbare Tablette
ES2445041T3 (es) * 2002-01-16 2014-02-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Método para la preparación de telmisartán amorfo

Also Published As

Publication number Publication date
JP2008524136A (ja) 2008-07-10
TW200637546A (en) 2006-11-01
PE20060768A1 (es) 2006-09-29
BRPI0519656A2 (pt) 2009-03-03
IL183944A0 (en) 2007-10-31
AU2005315855A1 (en) 2006-06-22
UY29274A1 (es) 2006-07-31
CA2589493A1 (en) 2006-06-22
WO2006063737A1 (en) 2006-06-22
CN101080225A (zh) 2007-11-28
EP1827424A1 (en) 2007-09-05
KR20070097511A (ko) 2007-10-04
NO20072325L (no) 2007-07-06
EA200701159A1 (ru) 2007-12-28

Similar Documents

Publication Publication Date Title
AR052052A1 (es) Terapia de combinacion
MX348005B (es) Dispositivo implantable de liberación de fármacos y métodos para tratar la vejiga y otras vesículas o lúmenes corporales.
AR068185A1 (es) Composiciones de tabletas de desintegracion oral de lamotrigina
EA200870325A1 (ru) Лекарственные формы для введения комбинаций лекарственных средств
CL2008003595A1 (es) Compuestos heterociclicos nitrogenados, antagonistas del receptor de taquiquinina; agente farmaceutico que comprende el compuesto; y uso en la profilaxis o el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal o una enfermedad del sistema nervioso central.
TW200631578A (en) Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
PE20040134A1 (es) Forma de dosificacion de una vez al dia de pramipexol
AR062860A1 (es) Combinaciones terapeuticas 482
UY27532A1 (es) Forma de dosificación de liberación controlada dual.
AR045179A1 (es) Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
NO20072931L (no) Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva
AR051968A1 (es) Metodos y composiciones que utilizan inhibidores de jnk para el tratamiento y manejo de la lesion del sistema nervioso central
CL2011000625A1 (es) Preparación sólida que comprende 2-etoxi-1-((2'-(5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil-4-il)metil)-1h-bencimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metilo, un agente regulador de ph y un compuesto antagonista de calcio; y metodos para utilizar y mejorar disolucion del compuesto en la preparacion solida.
AR034517A1 (es) Formulacion farmaceutica
CL2007002875A1 (es) Composicion farmaceutica recubierta por una pelicula que comprende capecitabina y al menos un disgregante, util en el tratamiento del cancer para pacientes que tienen dificultad para tragar las formas de dosificacion solidas orales.
ECSP078014A (es) Regimen de dosificacion para prasugrel
AR065139A1 (es) Medicamento para el tratamiento de la endometriosis
AR048370A1 (es) Composicion para mejorar funciones cognitivas y la memoria
UY26422A1 (es) Método para administrar un inhibidor de fosfodiesterasa 4
AR034975A1 (es) Metodo para el tratamiento del insomnio primario
AR038858A1 (es) Combinacion
CL2008003558A1 (es) Composicion farmaceutica que comprende valrubicina y sulfoxido de dimetilo en forma de dosis intravesical, util para tratar cancer a la vejiga.

Legal Events

Date Code Title Description
FB Suspension of granting procedure